Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific … – GlobeNewswire (press release)
|
Poseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific …
GlobeNewswire (press release) Significant T–cell memory: Greater than 70% of P-BCMA-101 cells possessed a stem cell memory phenotype (SCM), a highly desirable characteristic for CAR-T therapies, creating a significant population of self-renewing multipotent progenitors capable of … |
